{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,18]],"date-time":"2024-08-18T00:09:25Z","timestamp":1723939765936},"reference-count":53,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,16]]},"DOI":"10.7759\/cureus.67034","type":"journal-article","created":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T01:12:37Z","timestamp":1723857157000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparative Mortality Rates of Vasoconstrictor Agents in the Management of Hepatorenal Syndrome: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Oluwatoba T","family":"Olayinka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaslin","family":"Orelus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mah Rukh","family":"Nisar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudrani","family":"Kotha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabaa I","family":"Saad-Omer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shivani","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann Kashmer","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Hepatorenal syndrome. (2024). Accessed. April 8, 2024: https:\/\/www.uptodate.com\/contents\/hepatorenal-syndrome."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v9.i6.293","article-title":"Hepatorenal syndrome: update on diagnosis and therapy","volume":"9","author":"Acevedo JG","year":"2017","unstructured":"Acevedo JG, Cramp ME. Hepatorenal syndrome: update on diagnosis and therapy. World J Hepatol. 2017, 9:293-9. 10.4254\/wjh.v9.i6.293","journal-title":"World J Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/lt.26072","article-title":"The current management of hepatorenal syndrome-acute kidney injury in the United States and the potential of terlipressin","volume":"27","author":"Flamm SL","year":"2021","unstructured":"Flamm SL, Brown K, Wadei HM, et al.. The current management of hepatorenal syndrome-acute kidney injury in the United States and the potential of terlipressin. Liver Transpl. 2021, 27:1191-202. 10.1002\/lt.26072","journal-title":"Liver Transpl"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfac025","article-title":"Management of acute renal replacement therapy in critically ill cirrhotic patients","volume":"15","author":"Del Risco-Zevallos J","year":"2022","unstructured":"Del Risco-Zevallos J, And\u00fajar AM, Pi\u00f1eiro G, et al.. Management of acute renal replacement therapy in critically ill cirrhotic patients. Clin Kidney J. 2022, 15:1060-70. 10.1093\/ckj\/sfac025","journal-title":"Clin Kidney J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1159\/000355739","article-title":"Hepatorenal syndrome and novel advances in its management","volume":"37","author":"Fabrizi F","year":"2013","unstructured":"Fabrizi F, Aghemo A, Messa P. Hepatorenal syndrome and novel advances in its management. Kidney Blood Press Res. 2013, 37:588-601. 10.1159\/000355739","journal-title":"Kidney Blood Press Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018, 69:182-236. 10.1016\/j.jhep.2018.03.019","journal-title":"J Hepatol"},{"key":"ref7","doi-asserted-by":"crossref","DOI":"10.1002\/hep.31884","article-title":"Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases","volume":"74","author":"Biggins S","year":"2021","unstructured":"Biggins S, Angeli P, Garcia\u2010Tsao G, et al.. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021, 74:1014-48.","journal-title":"Hepatology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510300430","article-title":"Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine","volume":"30","author":"G\u00fclberg V","year":"1999","unstructured":"G\u00fclberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology. 1999, 30:870-5. 10.1002\/hep.510300430","journal-title":"Hepatology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.34343","article-title":"Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study","volume":"36","author":"Duvoux C","year":"2002","unstructured":"Duvoux C, Zanditenas D, H\u00e9zode C, et al.. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology. 2002, 36:374-80. 10.1053\/jhep.2002.34343","journal-title":"Hepatology"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.04.010","article-title":"Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study","volume":"47","author":"Alessandria C","year":"2007","unstructured":"Alessandria C, Ottobrelli A, Debernardi-Venon W, et al.. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol. 2007, 47:499-505. 10.1016\/j.jhep.2007.04.010","journal-title":"J Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-006-9312-0","article-title":"Octreotide\/midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome","volume":"52","author":"Esrailian E","year":"2007","unstructured":"Esrailian E, Pantangco ER, Kyulo NL, Hu KQ, Runyon BA. Octreotide\/midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci. 2007, 52:742-8. 10.1007\/s10620-006-9312-0","journal-title":"Dig Dis Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(99)80025-7","article-title":"Octreotide in the treatment of the hepatorenal syndrome in cirrhotic patients","volume":"30","author":"Kaffy F","year":"1999","unstructured":"Kaffy F, Borderie C, Chagneau C, et al.. Octreotide in the treatment of the hepatorenal syndrome in cirrhotic patients. World J Hepatol. 1999, 30:174. 10.1016\/S0168-8278(99)80025-7","journal-title":"World J Hepatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50276","article-title":"Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study","volume":"38","author":"Pomier-Layrargues G","year":"2003","unstructured":"Pomier-Layrargues G, Paquin SC, Hassoun Z, Lafortune M, Tran A. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology. 2003, 38:238-43. 10.1053\/jhep.2003.50276","journal-title":"Hepatology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh930","article-title":"Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study","volume":"20","author":"Kiser TH","year":"2005","unstructured":"Kiser TH, Fish DN, Obritsch MD, Jung R, MacLaren R, Parikh CR. Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study. Nephrol Dial Transplant. 2005, 20:1813-20. 10.1093\/ndt\/gfh930","journal-title":"Nephrol Dial Transplant"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/lt.22395","article-title":"Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1","volume":"17","author":"Boyer TD","year":"2011","unstructured":"Boyer TD, Sanyal AJ, Garcia-Tsao G, et al.. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1. Liver Transpl. 2011, 17:1328-32. 10.1002\/lt.22395","journal-title":"Liver Transpl"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12384","article-title":"Twenty-year longitudinal follow-up after orthotopic liver transplantation: a single-center experience of 313 consecutive cases","volume":"13","author":"Schoening WN","year":"2013","unstructured":"Schoening WN, Buescher N, Rademacher S, et al.. Twenty-year longitudinal follow-up after orthotopic liver transplantation: a single-center experience of 313 consecutive cases. Am J Transplant. 2013, 13:2384-94. 10.1111\/ajt.12384","journal-title":"Am J Transplant"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30208","article-title":"Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure","volume":"71","author":"Arora V","year":"2020","unstructured":"Arora V, Maiwall R, Rajan V, et al.. Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure. Hepatology. 2020, 71:600-10. 10.1002\/hep.30208","journal-title":"Hepatology"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.02.026","article-title":"Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1","volume":"150","author":"Boyer TD","year":"2016","unstructured":"Boyer TD, Sanyal AJ, Wong F, et al.. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology. 2016, 150:1579-89.e2. 10.1053\/j.gastro.2016.02.026","journal-title":"Gastroenterology"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27709","article-title":"Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial","volume":"62","author":"Cavallin M","year":"2015","unstructured":"Cavallin M, Kamath PS, Merli M, et al.. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial. Hepatology. 2015, 62:567-74. 10.1002\/hep.27709","journal-title":"Hepatology"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28396","article-title":"Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study","volume":"63","author":"Cavallin M","year":"2016","unstructured":"Cavallin M, Piano S, Romano A, et al.. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study. Hepatology. 2016, 63:983-92. 10.1002\/hep.28396","journal-title":"Hepatology"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9343(96)00075-7","article-title":"Is the administration of dopamine associated with adverse or favorable outcomes in acute renal failure?","volume":"101","author":"Chertow GM","year":"1996","unstructured":"Chertow GM, Sayegh MH, Allgren RL, et al.. Is the administration of dopamine associated with adverse or favorable outcomes in acute renal failure?. Am J Med. 1996, 101:49-53. 10.1016\/s0002-9343(96)00075-7","journal-title":"Am J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.675948","article-title":"Norepinephrine is more effective than midodrine\/octreotide in patients with hepatorenal syndrome-acute kidney injury: a randomized controlled trial","volume":"12","author":"El-Desoki Mahmoud EI","year":"2021","unstructured":"El-Desoki Mahmoud EI, Abdelaziz DH, Abd-Elsalam S, Mansour NO. Norepinephrine is more effective than midodrine\/octreotide in patients with hepatorenal syndrome-acute kidney injury: a randomized controlled trial. Front Pharmacol. 2021, 12:675948. 10.3389\/fphar.2021.675948","journal-title":"Front Pharmacol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.21608\/asmj.2023.298308","article-title":"Terlipressin versus norepinephrine in the management of type 1 hepatorenal syndrome patients","volume":"74","author":"Fathallah RMAEA","year":"2023","unstructured":"Fathallah RMAEA, Nashed SW, El-Ansary AM, et al.. Terlipressin versus norepinephrine in the management of type 1 hepatorenal syndrome patients. Ain Shams Med J. 2023, 74:153-71. 10.21608\/asmj.2023.298308","journal-title":"Ain Shams Med J"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.26106","article-title":"One-year results of the ICON (Ionic versus non-ionic contrast to obviate worsening nephropathy after angioplasty in chronic renal failure patients) study","volume":"87","author":"Giustino G","year":"2016","unstructured":"Giustino G, Baber U, Mastoris I, et al..  One-year results of the ICON (Ionic versus non-ionic contrast to obviate worsening nephropathy after angioplasty in chronic renal failure patients) study. Catheter Cardiovasc Interv. 2016, 87:703-9. 10.1002\/ccd.26106","journal-title":"Catheter Cardiovasc Interv"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2013.02.242","article-title":"Noradrenaline is equally effective as terlipressin in reversal of type 1 hepatorenal syndrome: A randomized prospective study","volume":"3","author":"Indrabi RA","year":"2013","unstructured":"Indrabi RA, Javid G, Zargar SA, et al.. Noradrenaline is equally effective as terlipressin in reversal of type 1 hepatorenal syndrome: A randomized prospective study. J Clin Exp Hepatol. 2013, 3:S97. 10.1016\/j.jceh.2013.02.242","journal-title":"J Clin Exp Hepatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1097\/CCE.0000000000000890","article-title":"Role of terlipressin in patients with hepatorenal syndrome-acute kidney injury admitted to the ICU: a substudy of the CONFIRM trial","volume":"5","author":"Karvellas CJ","year":"2023","unstructured":"Karvellas CJ, Subramanian R, Olson JC, Jamil K. Role of terlipressin in patients with hepatorenal syndrome-acute kidney injury admitted to the ICU: a substudy of the CONFIRM trial. Crit Care Explor. 2023, 5:e0890. 10.1097\/CCE.0000000000000890","journal-title":"Crit Care Explor"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-09505-1","article-title":"Safety and efficacy of terlipressin in acute-on-chronic liver failure with hepatorenal syndrome-acute kidney injury (HRS-AKI): a prospective cohort study","volume":"12","author":"Kulkarni AV","year":"2022","unstructured":"Kulkarni AV, Ravikumar ST, Tevethia H, et al.. Safety and efficacy of terlipressin in acute-on-chronic liver failure with hepatorenal syndrome-acute kidney injury (HRS-AKI): a prospective cohort study. Sci Rep. 2022, 12:5503. 10.1038\/s41598-022-09505-1","journal-title":"Sci Rep"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.02.024","article-title":"Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study","volume":"134","author":"Mart\u00edn-Llah\u00ed M","year":"2008","unstructured":"Mart\u00edn-Llah\u00ed M, P\u00e9pin MN, Guevara M, et al.. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology. 2008, 134:1352-9. 10.1053\/j.gastro.2008.02.024","journal-title":"Gastroenterology"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15836","article-title":"Real-world treatment patterns and outcomes using terlipressin in 203 patients with the hepatorenal syndrome","volume":"52","author":"Moore K","year":"2020","unstructured":"Moore K, Jamil K, Verleger K, et al.. Real-world treatment patterns and outcomes using terlipressin in 203 patients with the hepatorenal syndrome. Aliment Pharmacol Ther. 2020, 52:351-8. 10.1111\/apt.15836","journal-title":"Aliment Pharmacol Ther"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.18203\/2349-3933.ijam20213215","article-title":"A prospective study to compare the efficacy of noradrenaline verses terlipressin in hepatorenal syndrome in patients with advanced cirrhosis","volume":"8","author":"Nayyar S","year":"2021","unstructured":"Nayyar S, Kaur R, Mohan G, et al.. A prospective study to compare the efficacy of noradrenaline verses terlipressin in hepatorenal syndrome in patients with advanced cirrhosis. Int J Adv Med. 2021, 8:1312-18. 10.18203\/2349-3933.ijam20213215","journal-title":"Int J Adv Med"},{"key":"ref32","article-title":"Effectiveness of terlipressin and albumin for the treatment of hepatorenal syndrome","volume":"15","author":"Nowsherwan","year":"2021","unstructured":"Nowsherwan, Ali A, Ali A, et al.. Effectiveness of terlipressin and albumin for the treatment of hepatorenal syndrome. Pak J Med Health Sci. 2021, 15:809-11.","journal-title":"Pak J Med Health Sci"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.35819","article-title":"Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study","volume":"36","author":"Ortega R","year":"2002","unstructured":"Ortega R, Gin\u00e8s P, Uriz J, et al.. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology. 2002, 36:941-8. 10.1053\/jhep.2002.35819","journal-title":"Hepatology"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/s12664-018-0876-3","article-title":"Noradrenaline versus terlipressin in the management of type 1 hepatorenal syndrome: a randomized controlled study","volume":"37","author":"Saif RU","year":"2018","unstructured":"Saif RU, Dar HA, Sofi SM, Andrabi MS, Javid G, Zargar SA. Noradrenaline versus terlipressin in the management of type 1 hepatorenal syndrome: a randomized controlled study. Indian J Gastroenterol. 2018, 37:424-9. 10.1007\/s12664-018-0876-3","journal-title":"Indian J Gastroenterol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.02.014","article-title":"A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome","volume":"134","author":"Sanyal AJ","year":"2008","unstructured":"Sanyal AJ, Boyer T, Garcia-Tsao G, et al.. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology. 2008, 134:1360-8. 10.1053\/j.gastro.2008.02.014","journal-title":"Gastroenterology"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14052","article-title":"Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies","volume":"45","author":"Sanyal AJ","year":"2017","unstructured":"Sanyal AJ, Boyer TD, Frederick RT, et al.. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies. Aliment Pharmacol Ther. 2017, 45:1390-402. 10.1111\/apt.14052","journal-title":"Aliment Pharmacol Ther"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.01.012","article-title":"Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study","volume":"56","author":"Singh V","year":"2012","unstructured":"Singh V, Ghosh S, Singh B, et al.. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol. 2012, 56:1293-8. 10.1016\/j.jhep.2012.01.012","journal-title":"J Hepatol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2003.02934.x","article-title":"Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial","volume":"18","author":"Solanki P","year":"2003","unstructured":"Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol. 2003, 18:152-6. 10.1046\/j.1440-1746.2003.02934.x","journal-title":"J Gastroenterol Hepatol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2015.08.003","article-title":"Randomized controlled trial comparing the efficacy of terlipressin and albumin with a combination of concurrent dopamine, furosemide, and albumin in hepatorenal syndrome","volume":"5","author":"Srivastava S","year":"2015","unstructured":"Srivastava S, Shalimar, Vishnubhatla S, Prakash S, Sharma H, Thakur B, Acharya SK. Randomized controlled trial comparing the efficacy of terlipressin and albumin with a combination of concurrent dopamine, furosemide, and albumin in hepatorenal syndrome. J Clin Exp Hepatol. 2015, 5:276-85. 10.1016\/j.jceh.2015.08.003","journal-title":"J Clin Exp Hepatol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.53350\/pjmhs22162552","article-title":"Comparison of terlipressin plus human albumin with norepineprine plus human albumin in hepatorenal renal syndrome","volume":"16","author":"Ullah N","year":"2022","unstructured":"Ullah N, Muzammil M, Tahir M, et al.. Comparison of terlipressin plus human albumin with norepineprine plus human albumin in hepatorenal renal syndrome. Pak J Med Health Sci. 2022, 16:02. 10.53350\/pjmhs22162552","journal-title":"Pak J Med Health Sci"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0000000000000132","article-title":"The effect of terlipressin on renal replacement therapy in patients with hepatorenal syndrome","volume":"4","author":"Velez JC","year":"2023","unstructured":"Velez JC, Wong F, Reddy KR, et al.. The effect of terlipressin on renal replacement therapy in patients with hepatorenal syndrome. Kidney360. 2023, 4:1030-8. 10.34067\/KID.0000000000000132","journal-title":"Kidney360"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2016.07.016","article-title":"Terlipressin improves renal function and reverses hepatorenal syndrome in patients with systemic inflammatory response syndrome","volume":"15","author":"Wong F","year":"2017","unstructured":"Wong F, Pappas SC, Boyer TD, Sanyal AJ, Bajaj JS, Escalante S, Jamil K. Terlipressin improves renal function and reverses hepatorenal syndrome in patients with systemic inflammatory response syndrome. Clin Gastroenterol Hepatol. 2017, 15:266-72.e1. 10.1016\/j.cgh.2016.07.016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2008290","article-title":"Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome","volume":"384","author":"Wong F","year":"2021","unstructured":"Wong F, Pappas SC, Curry MP, et al.. Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. N Engl J Med. 2021, 384:818-28. 10.1056\/NEJMoa2008290","journal-title":"N Engl J Med"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17195","article-title":"Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute-on-chronic liver failure","volume":"56","author":"Wong F","year":"2022","unstructured":"Wong F, Pappas SC, Reddy KR, Vargas H, Curry MP, Sanyal A, Jamil K. Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute-on-chronic liver failure. Aliment Pharmacol Ther. 2022, 56:1284-93. 10.1111\/apt.17195","journal-title":"Aliment Pharmacol Ther"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1097\/01.NAJ.0000919728.07518.8e","article-title":"First drug for treating hepatorenal syndrome","volume":"123","author":"Aschenbrenner DS","year":"2023","unstructured":"Aschenbrenner DS. First drug for treating hepatorenal syndrome. Am J Nurs. 2023, 123:27. 10.1097\/01.NAJ.0000919728.07518.8e","journal-title":"Am J Nurs"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8810813","article-title":"Adipose-derived stem cells: current applications and future directions in the regeneration of multiple tissues","volume":"2020","author":"Zhang J","year":"2020","unstructured":"Zhang J, Liu Y, Chen Y, et al.. Adipose-derived stem cells: current applications and future directions in the regeneration of multiple tissues. Stem Cells Int. 2020, 2020:8810813. 10.1155\/2020\/8810813","journal-title":"Stem Cells Int"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0000000000000217","article-title":"Good enough? Terlipressin, hepatorenal syndrome, and the usage of RRT","volume":"4","author":"Belcher JM","year":"2023","unstructured":"Belcher JM. Good enough? Terlipressin, hepatorenal syndrome, and the usage of RRT. Kidney360. 2023, 4:1011-13. 10.34067\/KID.0000000000000217","journal-title":"Kidney360"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2024.101495","article-title":"Efficacy and safety of terlipressin and albumin vs. noradrenaline and albumin in adult patients with hepatorenal syndrome: a systematic review and meta-analysis","volume":"29","author":"Malik A","year":"2024","unstructured":"Malik A, Malik MI, Qureshi S, Nadir A. Efficacy and safety of terlipressin and albumin vs. noradrenaline and albumin in adult patients with hepatorenal syndrome: a systematic review and meta-analysis. Ann Hepatol. 2024, 29:101495. 10.1016\/j.aohep.2024.101495","journal-title":"Ann Hepatol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000010431","article-title":"Terlipressin in the treatment of hepatorenal syndrome: a systematic review and meta-analysis","volume":"97","author":"Wang H","year":"2018","unstructured":"Wang H, Liu A, Bo W, Feng X, Hu Y. Terlipressin in the treatment of hepatorenal syndrome: a systematic review and meta-analysis. Medicine (Baltimore). 2018, 97:e0431. 10.1097\/MD.0000000000010431","journal-title":"Medicine (Baltimore)"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13912","article-title":"Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1","volume":"45","author":"Gifford FJ","year":"2017","unstructured":"Gifford FJ, Morling JR, Fallowfield JA. Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1. Aliment Pharmacol Ther. 2017, 45:593-603. 10.1111\/apt.13912","journal-title":"Aliment Pharmacol Ther"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011532.pub2","article-title":"Terlipressin versus other vasoactive drugs for hepatorenal syndrome","volume":"9","author":"Israelsen M","year":"2017","unstructured":"Israelsen M, Krag A, Allegretti AS, Jovani M, Goldin AH, Winter RW, Gluud LL. Terlipressin versus other vasoactive drugs for hepatorenal syndrome. Cochrane Database Syst Rev. 2017, 9:CD011532. 10.1002\/14651858.CD011532.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000005595","article-title":"The comparative effectiveness of vasoactive treatments for hepatorenal syndrome: a systematic review and network meta-analysis","volume":"50","author":"Pitre T","year":"2022","unstructured":"Pitre T, Kiflen M, Helmeczi W, et al.. The comparative effectiveness of vasoactive treatments for hepatorenal syndrome: a systematic review and network meta-analysis. Crit Care Med. 2022, 50:1419-29. 10.1097\/CCM.0000000000005595","journal-title":"Crit Care Med"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.12600","article-title":"Terlipressin effect on hepatorenal syndrome: updated meta-analysis of randomized controlled trials","volume":"5","author":"Mohamed MM","year":"2021","unstructured":"Mohamed MM, Rauf A, Adam A, Kheiri B, Lacasse A, El-Halawany H. Terlipressin effect on hepatorenal syndrome: updated meta-analysis of randomized controlled trials. JGH Open. 2021, 5:896-901. 10.1002\/jgh3.12600","journal-title":"JGH Open"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/269555-comparative-mortality-rates-of-vasoconstrictor-agents-in-the-management-of-hepatorenal-syndrome-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T01:12:44Z","timestamp":1723857164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/269555-comparative-mortality-rates-of-vasoconstrictor-agents-in-the-management-of-hepatorenal-syndrome-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,16]]},"references-count":53,"URL":"https:\/\/doi.org\/10.7759\/cureus.67034","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,16]]}}}